<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7321236\results\search\disease\results.xml">
  <result pre="of thirty four approved and on-trial protease inhibitors was performed." exact="Increased" post="3D structural similarity between the SARS-CoV-2 main protease, the"/>
  <result pre="inhibitors, with several of them exhibiting estimated free binding energy" exact="lower" post="than âˆ’8.00 kcal/mol and better prediction results than reference"/>
  <result pre="the promising in silico results may warrant further evaluation for" exact="viral" post="anticipation. DPP-4 inhibitors with anti-viral action may be more"/>
  <result pre="young people usually develop mild symptoms, it can cause severe" exact="lower" post="respiratory disease affecting mostly the elderly and individuals with"/>
  <result pre="people usually develop mild symptoms, it can cause severe lower" exact="respiratory" post="disease affecting mostly the elderly and individuals with other"/>
  <result pre="usually develop mild symptoms, it can cause severe lower respiratory" exact="disease" post="affecting mostly the elderly and individuals with other co-morbidities"/>
  <result pre="mostly the elderly and individuals with other co-morbidities such as" exact="cardiovascular" post="problems, pre-existing respiratory disease, diabetes, hypertension or cancer [1]."/>
  <result pre="and individuals with other co-morbidities such as cardiovascular problems, pre-existing" exact="respiratory" post="disease, diabetes, hypertension or cancer [1]. SARS-CoV-2 belongs to"/>
  <result pre="other co-morbidities such as cardiovascular problems, pre-existing respiratory disease, diabetes," exact="hypertension" post="or cancer [1]. SARS-CoV-2 belongs to the Î²CoV genera"/>
  <result pre="such as cardiovascular problems, pre-existing respiratory disease, diabetes, hypertension or" exact="cancer" post="[1]. SARS-CoV-2 belongs to the Î²CoV genera of the"/>
  <result pre="as RDRP inhibitors while lopinavir, ritonavir [5,6] and danoprevir are" exact="viral" post="protease inhibitors. In addition, drugs aiming to prevent the"/>
  <result pre="drugs aiming to prevent the entrance and formation of the" exact="viral" post="particles have been proposed, such as chloroquine, hydroxychloroquine [7]"/>
  <result pre="of the first SARS-CoV-2 main protease structure (Mpro) to the" exact="Protein" post="Data Bank, on March 2020, several in silico studies"/>
  <result pre="are ribavirin, a nucleoside analogue used for the treatment of" exact="Lassa fever" post="virus, influenza A and B and HCV [12]; telbivudine,"/>
  <result pre="protease inhibitors [20]. Among the main proteolytic enzymes are the" exact="viral" post="proteases of HIV-1, with more than fifteen approved or"/>
  <result pre="agents. DPP-4 inhibitors, gliptins, are used for the treatment of" exact="type II" post="diabetes, with seventeen drugs of this type mentioned in"/>
  <result pre="recognition motifs are concerned, the SARS-CoV-2 main protease cleaves the" exact="viral" post="polyprotein at no less than 11 sites, recognizing the"/>
  <result pre="the enzyme. 2. Results and Discussion 2.1. The 3D Structure" exact="Protein" post="Alignment Since the 3D structure of the active site"/>
  <result pre="The HIV-1 protease inhibitors ritonavir and lopinavir showed a little" exact="lower" post="predicted activity, with free binding energies of âˆ’8.96 and"/>
  <result pre="the expected inhibitory action of these compounds is to be" exact="lower" post="than that predicted based on their binding energy to"/>
  <result pre="of the 24 compounds which were selected for evaluation exhibited" exact="lower" post="estimated binding energy than the initial inhibitor of the"/>
  <result pre="expected inhibitory action of inogatran and edoxaban are to be" exact="lower" post="than that predicted based on their relative binding energy"/>
  <result pre="Î±-thrombin inhibitors. The DPP-4 inhibitors developed for the treatment of" exact="diabetes" post="type II as well as the Î±-thrombin and Factor"/>
  <result pre="inhibitors. The DPP-4 inhibitors developed for the treatment of diabetes" exact="type II" post="as well as the Î±-thrombin and Factor Xa inhibitors,"/>
  <result pre="may be worth consideration for patients already being treated for" exact="type II" post="diabetes or with anti-coagulants. Moreover, higher platelet count and"/>
  <result pre="worth consideration for patients already being treated for type II" exact="diabetes" post="or with anti-coagulants. Moreover, higher platelet count and increased"/>
  <result pre="increased coagulation features are observed in COVID-19 patients with severe" exact="pneumonia" post="compared to patients with non SARS-CoV-2-induced pneumonia. Furthermore, according"/>
  <result pre="by heparin administration reduced mortality of COVID-19 patients with severe" exact="pneumonia" post="and markedly elevated D-dimers [35]. In general, the results"/>
  <result pre="in the market. 3. Experimental Part 3.1. The 3D Structure" exact="Protein" post="Alignment The 3D alignment was performed between the 3D"/>
  <result pre="ID: 4BTI) and (f) ACE-2 (PDB ID:2YDM) using the RCSB" exact="Protein" post="Data Bank 3D structure protein comparison tool (jFATCAT flexible"/>
  <result pre="indicator of the probability of the compounds to form a" exact="stable" post="complex with the selected enzyme target and consequently the"/>
  <result pre="be effective enzyme inhibitors. The protein structures chosen from the" exact="Protein" post="Data Bank and the docking center and docking box"/>
  <result pre="in complex with an inhibitor that was released in the" exact="Protein" post="Data Bank on March 18th, 2020 and was the"/>
  <result pre="of the SARS-CoV-2 main protease with the HIV-1 and HCV" exact="viral" post="proteases as well as with the human proteases DPP-4,"/>
  <result pre="Xa inhibitors. Twenty five of them exhibited estimated binding energy" exact="lower" post="than the reference inhibitor N3, and twenty one lower"/>
  <result pre="energy lower than the reference inhibitor N3, and twenty one" exact="lower" post="than âˆ’8.00 kcal molâˆ’1. Several of the most promising"/>
  <result pre="of the evaluated compounds showed better results, as characterized by" exact="lower" post="predicted free binding energy and high preference for binding"/>
  <result pre="anti-viral activity. The DPP-4 inhibitors developed for the treatment of" exact="type II" post="diabetes, as well as Î±-thrombin and Factor Xa inhibitors"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="RDRP RNA-dependent RNA polymerase DPP-4 dipeptidyl peptidase-4 References References 1.Coronavirus" exact="Disease" post="(COVID-19) Outbreak SituationAvailable online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019(accessed on 16 April 2020)"/>
  <result pre="2019 novel human pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 4.ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.et al.A pneumonia outbreak"/>
  <result pre="novel human pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 4.ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.et al.A pneumonia outbreak"/>
  <result pre="with atypical pneumonia after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 4.ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.20206162010.1038/s41421-020-0156-032194981 8.UBC, Apeiron Biologics to Trial Coronavirus"/>
  <result pre="(3CLpro): An in silico screening of Alkaloids and Terpenoids from" exact="African" post="medicinal plantsJ. Biomol. Struct. Dyn.2020511910.1080/07391102.2020.176486832367767 19.TsujiM.Potential anti-SARS-CoV-2 drug candidates"/>
  <result pre="ONE20127e3575910.1371/journal.pone.003575922558217 25.LankasG.R.LeitingB.RoyR.S.EiermannG.J.BeconiM.G.BiftuT.ChanC.C.EdmondsonS.FeeneyW.P.HeH.et al.Dipeptidyl peptidase IV inhibition for the treatment of" exact="type 2" post="diabetes: Potential importance of selectivity over dipeptidyl peptidases 8"/>
  <result pre="discovery of its inhibitorsNature201910.1038/s41586-020-2223-y 35.YinS.HuangM.LiD.TangN.Difference of coagulation features between severe" exact="pneumonia" post="induced by SARS-CoV2 and non-SARS-CoV2J. Thromb. Thrombolysis20201410.1007/s11239-020-02105-832246317 36.MadejT.LanczyckiC.J.ZhangD.ThiessenP.A.GeerR.C.Marchler-BauerA.BryantS.H.MMDB and"/>
  <result pre="Tracking structural similarities between macromolecular complexesNucleic Acids Res.201442D297D30310.1093/nar/gkt120824319143 37.RCSB PDB" exact="Protein" post="Comparison ToolAvailable online: http://www.rcsb.org/pdb/workbench/workbench.do(accessed on 12 March 2020) 38.BikadiZ.HazaiE.Application"/>
  <result pre="3 Study in Combination with BMS-790052 and BMS-650032 in Japanese" exact="Hepatitis" post="C Virus (HCV) PatientsAvailable online: https://clinicaltrials.gov/(accessed on 5 April"/>
  <result pre="https://clinicaltrials.gov/(accessed on 5 April 2020) 42.KumadaH.SuzukiY.IkedaK.ToyotaJ.KarinoY.ChayamaK.KawakamiY.IdoA.YamamotoK.TakaguchiK.et al.Daclatasvir plus asunaprevir for" exact="chronic" post="HCV genotype 1b infectionHepatology2014592083209110.1002/hep.2711324604476 43.HuangF.MoschettiV.LangB.HalabiA.Petersen-SyllaM.YongC.-L.ElgadiM.Pharmacokinetics, Safety, and Tolerability of"/>
  <result pre="infectionHepatology2014592083209110.1002/hep.2711324604476 43.HuangF.MoschettiV.LangB.HalabiA.Petersen-SyllaM.YongC.-L.ElgadiM.Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with" exact="Renal" post="ImpairmentAntimicrob. Agents Chemother.20145925125710.1128/AAC.03359-1425348520 44.NguyenD.L.MorganT.R.Management of Adverse Events during the"/>
  <result pre="Agents Chemother.20145925125710.1128/AAC.03359-1425348520 44.NguyenD.L.MorganT.R.Management of Adverse Events during the Treatment of" exact="Chronic" post="Hepatitis C InfectionClin. Liver Dis. (Hoboken)20121545710.1002/cld.3325688295 45.LawitzE.SulkowskiM.JacobsonI.KraftW.K.MaliakkalB.Al-IbrahimM.GordonS.C.KwoP.RockstrohJ.K.PanorchanP.et al.Characterization of"/>
  <result pre="Chemother.20145925125710.1128/AAC.03359-1425348520 44.NguyenD.L.MorganT.R.Management of Adverse Events during the Treatment of Chronic" exact="Hepatitis" post="C InfectionClin. Liver Dis. (Hoboken)20121545710.1002/cld.3325688295 45.LawitzE.SulkowskiM.JacobsonI.KraftW.K.MaliakkalB.Al-IbrahimM.GordonS.C.KwoP.RockstrohJ.K.PanorchanP.et al.Characterization of Vaniprevir,"/>
  <result pre="C InfectionClin. Liver Dis. (Hoboken)20121545710.1002/cld.3325688295 45.LawitzE.SulkowskiM.JacobsonI.KraftW.K.MaliakkalB.Al-IbrahimM.GordonS.C.KwoP.RockstrohJ.K.PanorchanP.et al.Characterization of Vaniprevir, a" exact="Hepatitis" post="C Virus NS3/4A Protease Inhibitor, in Patients With HCV"/>
  <result pre="PharmacokineticsAntivir. Res.20139921422010.1016/j.antiviral.2013.05.01523747481 46.FDA Drug Safety Communication: FDA Adds Warnings about" exact="Heart Failure" post="Risk to Labels of Type 2 Diabetes Medicines Containing"/>
  <result pre="Res.20139921422010.1016/j.antiviral.2013.05.01523747481 46.FDA Drug Safety Communication: FDA Adds Warnings about Heart" exact="Failure" post="Risk to Labels of Type 2 Diabetes Medicines Containing"/>
  <result pre="FDA Adds Warnings about Heart Failure Risk to Labels of" exact="Type 2" post="Diabetes Medicines Containing Saxagliptin and AlogliptinAvailable online: https://www.fda.gov/(accessed on"/>
  <result pre="Warnings about Heart Failure Risk to Labels of Type 2" exact="Diabetes" post="Medicines Containing Saxagliptin and AlogliptinAvailable online: https://www.fda.gov/(accessed on 5"/>
  <result pre="risk of hypoglycaemia: Systematic review and meta-analysisBMJ2016353i223110.1136/bmj.i223127142267 49.DPP-4 Inhibitors for" exact="Type 2" post="Diabetes: Drug Safety Communicationâ€&quot;May Cause Severe Joint PainFDARockville, MD,"/>
  <result pre="49.DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communicationâ€&quot;May Cause" exact="Severe" post="Joint PainFDARockville, MD, USA2015 50.OnglyzaAvailable online: https://www.rxlist.com/onglyza-drug.htm(accessed on 5"/>
  <result pre="Inhibitors for Type 2 Diabetes: Drug Safety Communicationâ€&quot;May Cause Severe" exact="Joint" post="PainFDARockville, MD, USA2015 50.OnglyzaAvailable online: https://www.rxlist.com/onglyza-drug.htm(accessed on 5 April"/>
  <result pre="MD, USA2015 50.OnglyzaAvailable online: https://www.rxlist.com/onglyza-drug.htm(accessed on 5 April 2020) 51.collab:" exact="American" post="Society of Health-System PharmacistsSitagliptin Phosphate Monograph for ProfessionalsAvailable online:"/>
  <result pre="2011 Boehringer-Ingelheim Gastrointestinal events [43] Narlaprevir ChEMBL1255891 Approved Schering, â&quot;ž-Pharm" exact="Pregnancy" post="lactation, severe neutropenia [44] Sovaprevir ChEMBL2105750 Investigational, received Fast"/>
  <result pre="events [43] Narlaprevir ChEMBL1255891 Approved Schering, â&quot;ž-Pharm Pregnancy lactation, severe" exact="neutropenia" post="[44] Sovaprevir ChEMBL2105750 Investigational, received Fast Track status from"/>
  <result pre="[45] DPP-4 inhibitors Alogliptin ChEMBL376359 Approved 2013 Takeda Pharmaceutical Company" exact="Increased" post="risk of heart failure [46] Anagliptin - Approved in"/>
  <result pre="Alogliptin ChEMBL376359 Approved 2013 Takeda Pharmaceutical Company Increased risk of" exact="heart" post="failure [46] Anagliptin - Approved in Japan 2012 Sanwa"/>
  <result pre="known yet Evogliptin ChEMBL1779710 Approved 2015 Dong-A ST Headache, nasopharyngitis," exact="upper respiratory tract infection" post="[47] Gemigliptin - Approved 2011 LG Life Sciences Generally"/>
  <result pre="yet Evogliptin ChEMBL1779710 Approved 2015 Dong-A ST Headache, nasopharyngitis, upper" exact="respiratory" post="tract infection [47] Gemigliptin - Approved 2011 LG Life"/>
  <result pre="ChEMBL1779710 Approved 2015 Dong-A ST Headache, nasopharyngitis, upper respiratory tract" exact="infection" post="[47] Gemigliptin - Approved 2011 LG Life Sciences Generally"/>
  <result pre="well tolerated Saxagliptin ChEMBL385517 Approved 2009 Bristol-Myers Squibb; AstraZeneca Upper" exact="respiratory" post="tract infection, may cause joint pain [49,50] Sitagliptin ChEMBL1422"/>
  <result pre="Approved 2006 Merck &amp;amp; Co. Headache, swelling of the legs," exact="upper respiratory tract infection" post="[51] Teneligliptin - Approved in Japan 2012 Mitsubishi Tanabe"/>
  <result pre="2006 Merck &amp;amp; Co. Headache, swelling of the legs, upper" exact="respiratory" post="tract infection [51] Teneligliptin - Approved in Japan 2012"/>
  <result pre="&amp;amp; Co. Headache, swelling of the legs, upper respiratory tract" exact="infection" post="[51] Teneligliptin - Approved in Japan 2012 Mitsubishi Tanabe"/>
  <result pre="Approved 2002 Eagle Pharmaceuticals Bleeding from the bladder, blurred vision," exact="chest" post="pain, dizziness, fever [53] Inogatran ChEMBL114715 Approved 2016 AstraZeneca"/>
  <result pre="ache, abnormal results of blood tests that measure liver function," exact="anemia" post="[57] Otamixaban - Ended at phase III Sanofi -"/>
 </snippets>
</snippetsTree>
